Unravelling the disease mechanism for TSPYL1 deficiency

Gunnar Buyse¹, Michela Di Michele², Anouck Wijgaerts³, Sophie Louwette³, Christine Wittevrongel³, Chantal Thys³, Kate Downes^{4,5}, Berten Ceulemans⁶, Hilde Van Esch^{7,8}, Chris Van Geet¹, Kathleen Freson^{3*}

¹Department of pediatric neurology, University Hospitals Leuven, Leuven, Belgium

²Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, Université de Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier, Montpellier, France

³Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium

⁴East Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK

⁵Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0PT, UK

⁶Department of pediatric neurology, University hospital, University of Antwerp, Antwerp, Belgium

⁷Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium

⁸Laboratory for the Genetics of Cognition, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Address for correspondence: *Kathleen Freson, Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O&N1, Herestraat 49, Box 911, 3000 Leuven, Belgium; e-mail: kathleen.freson@kuleuven.be; Tel: 32-16322707, Fax: 32-16345990

Abstract

We describe a lethal combined nervous and reproductive systems disease in three affected siblings of a consanguineous family. The phenotype was characterized by viscerautonomic dysfunction (neonatal bradycardia/apnea, feeding problems, hyperactive startle reflex), severe postnatal progressive neurological abnormalities (including abnormal neonatal cry, hypotonia, epilepsy, polyneuropathy, cerebral gray matter atrophy), visual impairment, testicular dysgenesis in males, and sudden death at infant age by brainstem-mediated cardiorespiratory arrest. Whole exome sequencing revealed a novel homozygous frameshift variant p.Val242GlufsTer52 in the TSPY-like 1 gene *TSPYL1*. The truncated TSPYL1 protein that lacks the nucleosome assembly protein (NAP) domain was retained in the Golgi of fibroblasts from the three patients while control fibroblasts express full length TSPYL1 in the nucleus. Proteomic analysis of nuclear extracts from fibroblasts identified 24 up- and 20 down-regulated proteins in the patients compared to five controls with “regulation of cell cycle” as the highest scored biological pathway

affected. TSPYL1 deficient cells had prolonged S and G2 phases with reduced cellular proliferation rates. Tspyl1 depletion in zebrafish mimicked the patients' phenotype with early lethality, defects in neurogenesis and cardiac dilation. In conclusion, this study reports the third pedigree with recessive *TSPYL1* variants, confirming that TSPYL1 deficiency leads to a combined nervous and reproductive systems disease, and provides for the first time insights into the disease mechanism.

Introduction

TSPY/TSPYL/SET/NAP1 (TTSN) superfamily proteins contain a nucleosome assembly protein (NAP) domain (1,2). Members of this family execute diverse functions, including cell cycle regulation, nucleosome assembly via histone binding, DNA replication, transcription and translation by direct protein interaction via their NAP domain. The best-characterized protein of all members is yeast NAP1, a 48-kDa polypeptide that binds histones and mediates nucleosome assembly (3). Human NAP1, encoded by *NAP1L1*, shares 54% amino acid similarity to yeast NAP1 and was found to participate in DNA replication and cell proliferation (4). Fluorescently tagged NAP1 is located in the nucleus in the S phase while it was found in the cytoplasm during the G₂ phase of the cell cycle, suggesting that NAP1 may be involved in shuttling histones between the cytoplasm and the nucleus (5).

Though many studies have illustrated the role of TTSN proteins in diverse cellular functions, our knowledge about their contribution to human pathology is very limited. Exome sequencing has recently detected autosomal dominant variants in *SET*, the gene for the SET nuclear protooncogene, as cause for non-syndromic intellectual disability in five unrelated patients (6). Two patients carried a missense variant in the NAP domain of SET while the others had frameshift variants. Functional studies using patient-derived cells were not performed but literature-based evidence for a role of SET in neurogenesis was provided (7,8). Knockout mice for *Set* die during embryonic development between days 11.5 and 12.5 and show multiple developmental defects such as cardiac edema and an open neural tube (9). In 2004, a homozygous frameshift variant in the TSPY-like 1 gene *TSPYL1* (MIM604714) was detected using linkage analysis and candidate gene Sanger sequencing in a large Amish pedigree where 21 children suffered from an autosomal recessive lethal disease characterized by sudden infant death

(from cardiac and respiratory arrest) with dysgenesis of the testes (SIDDT) in males (MIM608800) (10). This variant was predicted to result in a shorter protein that lacks the NAP domain and transfection studies in HELA cells showed how this truncated protein remained in the cytoplasm while wild type TSPYL1 was detected in the nucleus (10). No additional functional studies were performed and it was concluded that further elucidation of TSPYL1 function could shed light on the molecular control of embryogenesis of the nervous and reproductive systems via a complete novel pathway. A follow-up genetic study suggested a link between heterozygous missense variants in *TSPYL1* and anomalies of testicular development and function (11), but such association could not be confirmed by another study (12). Other studies did not find an association between *TSPYL1* variants and patient cohorts with isolated (i.e. otherwise normal children) sudden infant death (13,14). Only very recently, a homozygous *TSPYL1* frameshift variant was found in a girl diagnosed with SIDDT in a second non-Amish pedigree (15). This patient also suffered from mild T-cell lymphopenia and developed intractable epilepsy. Functional studies to unravel a role of TSPYL1 in the pathogenesis were again not performed in this case report.

With this study, we support the causal association between recessive loss of function variants in *TSPYL1* and a progressive combined nervous and reproductive systems disease including sudden infant death plus testicular dysgenesis in males. The functional impact of TSPYL1 depletion was studied by using two combined models, fibroblasts derived from three patients and zebrafish embryos. The homozygous frameshift variant resulted in a shorter TSPYL1 protein that retained in the Golgi from patients' fibroblasts and their proteome analysis pointed to a defect in cell cycle regulation. Tspyl1 depletion in zebrafish embryos mimicked phenotypes present in the patients.

Results

Clinical phenotype of affected patients

The consanguineous Turkish pedigree includes three affected siblings (P1, P2 and P4) who died of sudden cardiorespiratory arrest at the ages of 5, 9 and 5 months, respectively, and one healthy sibling (P3) (figure 1A). The healthy parents are second degree relatives. Patient 1 (P1; born in 2001) was a boy that presented at neonatal age with hypotonia, hypoventilation and obstructive and central apneas, swallow and feeding problems, hypogonadism, microgenitalia, and a progressive neurological disorder with regression, epilepsy and delayed visual development. Magnetic resonance imaging at 6 months revealed cerebral (gray matter) degeneration with evidence for poliodystrophy. He died at 9 months (sudden death by cardiorespiratory arrest). The phenotype of patient 2 (P2; born in 2004) was similar to that of his older sibling P1. He presented at neonatal age with bradycardia, hypoventilation and apneas (obstructive and central), abnormal cry (weak high pitched) and neurological behavior with excessive startle reflex and hypotonia, epilepsy (multifocal, seizure free under anti-epileptic treatment), delayed visual development, axonal polyneuropathy, severe feeding problems (tube feeding) and failure to thrive, and hypogonadism (vanishing testes) and microgenitalia. No structural brain (MRI at 3 weeks) or heart defects could be noticed. He died at 6 months (sudden death by cardiorespiratory arrest). The third affected sibling (P4; female, born in 2012) had an identical phenotype as her affected brothers, although slightly less severe (some motor development present). Prior to birth at postmenstrual age 38 weeks fetal bradycardias were observed. Her external genitalia were normal. She died at the age of 5 months (sudden death).

Whole exome sequencing identifies a homozygous TSPYL1 frameshift variant

Whole exome sequencing combined with homozygosity mapping for P2 revealed seven possible candidate variants (Supplementary Table 1). After validation of these homozygous variants in the affected and non-affected siblings, the variant in *TSPYL1* remained as the only possible candidate for the disorder. Patients P1, P2 and P4 were homozygous for the *TSPYL1* frameshift variant c.725_726 delTG while parents and the non-affected sibling P3 were heterozygous for this variant (Figure 1A). This variant (p.Val242GluTer52) results in a shorter protein of 292 amino acids compared to the normal 437 amino acid wild type TSPYL1 protein (Figure 1B). As *TSPYL1* is a single exon gene, the frameshift resulted in the generation of a truncated protein rather than leading to non-sense mediated decay. The mutant protein lacks the complete NAP domain and is thus predicted to localize in the cytoplasm instead of the cellular nucleus (10). The minor allele frequency of this frameshift variant in the gnomAD population database was 0.0021% but no homozygous carrier could be detected. Moreover, no homozygous Loss Of Function (LOF) variants in *TSPYL1* are reported in gnomAD.

TSPYL1 retention in Golgi of patients' fibroblasts

Protein expression studies using immunoblot analysis of subcellular protein extracts showed expression of TSPYL1 in the nuclear extract of fibroblasts from three unrelated healthy subjects (Figure 1C and Supplementary Figure 1). In contrast, fibroblasts of the three patients showed expression of a shorter TSPYL1 protein in the cytosol extracts. Further detailed subcellular expression studies were performed by immunostaining. While wild type TSPYL1 is expressed in the nucleus and weakly in the Golgi of normal fibroblasts, the shorter mutant TSPYL1 is mainly retained in the Golgi of the patients' fibroblasts (Figure 1D, Supplementary Figure 2).

Proteomic analysis of nuclear extracts from control and TSPYL1 deficient fibroblasts

2D-DIGE was used to analyze nuclear extracts from fibroblasts of five unrelated controls and the three patients (Supplementary figure 3). Equal amounts of proteins from control and patient nuclear extracts were labelled with Cy3 or Cy5 dyes, respectively. The quantitative comparison for a protein of the two samples co-resolved on the same gel was between the Cy3 or Cy5 signals, while the Cy2 was used as internal standard signal for this protein. Representative DIGE gels for proteins detected in nuclear extracts from a control and patient are shown in Supplementary figure 3. The Cy2, Cy3, and Cy5 channels of each gel were individually imaged and the comparisons of protein expression in 2D images were carried out using Decyder software. One-way ANOVA was performed on the normalized abundances of matched spots to compare similarity between the patients and controls according to expression patterns. Unsupervised Principle Component Analysis of the protein expression levels within each sample clearly separates the proteome of patients from controls (Supplementary figure 3).

Comparison between patient and control gels revealed that 48 protein spots varied in a statistically significant way ($p < 0.05$) with a patient/control fold change of at least 1.2 (Figure 2A). MALDI TOF-TOF MS analysis could identify 44 out of the 48 protein spots and the results of protein identifications are listed in Table 1. Several proteins were identified at multiple positions on the gel, suggestive for post-translational modifications and different isoforms. The final number of uniquely identified proteins modified in patients was 35 of which 15 were previously identified in cell nucleus. STRING analysis of these 15 nuclear proteins showed that most differentially expressed proteins regulate the cell cycle, are involved in cardiomyopathy and are located in the nuclear lumen (Supplementary table 2). Ingenuity Pathway Analysis software

was used to determine the most significant interaction networks and the “cell cycle” pathway resulted as most significant (Figure 2B).

Cell cycle and proliferation defect in TSPYL1 deficient fibroblasts

The patients' fibroblasts express a mutant protein that resides in the Golgi and therefore it is predicted that this protein cannot fulfill its normal function as regulator of cell cycling and nucleosome assembly. Cell cycle studies were performed by flow cytometry and significantly reduced G1 and increased S and G2 phases were detected in the patients' fibroblasts compared to controls (Figure 2C and D). Since a G2/M arrest can result in decreased cell proliferation, this was further studied. The patients' fibroblasts indeed showed a significant decreased cell proliferation rate compared to controls (Figure 2E).

Phenotype description of TSPYL1 depleted zebrafish embryos

ENSDART00000007482 is the orthologue gene for human *TSPYL1* in zebrafish. *Tspyl1* depletion in zebrafish was obtained using a splice morpholino (*tspyl1*-MO) that resulted in intron 4/5 retention (Supplementary figure 4). *Tspyl1* depleted embryos present with a deformed axis between 2 and 3 dpf (Figure 3A and B). These embryos were unable to independently remove their yolk sac and 50% died between 3 and 5 dpf (Figure 3C). In situ hybridization of whole-mount 1dpf embryos with probes for *lim3* and *slc35d3* showed a normal pituitary gland development (Supplementary figure 5) while staining for *pax2a* showed a complete absence of the optic stalk in *tspyl1* depleted embryos (Supplementary figure 6). *Tspyl1* depleted embryos have smaller heads and eyes. The formation of the optic stalk is part of the retinal neurogenesis in vertebrates and the expression of the proneural gene *atonal-homologue 5* (*ath5*) is closely

associated with the activation of retinal neurogenesis in all vertebrates (19,22). Transgenic Tg (*Ath5:eGFP*) embryos were used to characterize the development of the optic tectum and *tspyl1* depleted embryos at 5 dpf showed a significantly smaller optic tectum compared to control embryos, when corrected for the head size (Figures 3D and E). Transgenic Tg(*cmcl2:eGFP*) embryos carrying eGFP driven by heart-specific *cmcl2* promoter were used to study heart development (18). At 3dpf, *tspyl1* depleted embryos present with heart edema (Figures 3F and G) and dilated hearts (Figure 3H) with inverted looping and bradycardia (Figures 3H and I).

Discussion

The first causal association between the *TSPYL1* gene and human disease was reported in 2004, with the identification of a homozygous frameshift variant (c.457-458insG) in patients from a single Amish pedigree with a phenotype that included sudden infant death and dysgenesis of the testes syndrome in neurologically abnormal infants (MIM608800) (10). Our study now reports a recessive pathogenic *TSPYL1* variant in three siblings with a phenotype comparable to the Amish pedigree, confirming that *TSPYL1* deficiency leads to a combined nervous and reproductive systems disease. Our findings also provide for the first time insights into the disease mechanism. Patient fibroblast studies showed a Golgi (instead of the normal nuclear) localization of the mutated truncated *TSPYL1* protein, with consequent cell cycle dysregulation and cell proliferation defects.

The clinical phenotype in the Amish pedigree involved viscerautonomic nerve dysfunction early in life, with death due to abrupt cardiorespiratory arrest before 12 months of age. It included neonatal bradycardia, hypothermia, feeding problems with severe gastroesophageal reflux,

respiratory problems with laryngo/bronchospasms and apneas, abnormal cardiorespiratory pattern during sleep, hyperactive startle reflex, plus fetal testicular dysgenesis and ambiguous genitalia in males. The phenotype of the three affected siblings reported in this study was characterized by viscerautonomic dysfunction, bradycardias and hypoventilation/apneas, severe postnatal progressive neurological abnormalities (including abnormal neonatal cry and neurological behavior, hypotonia, epilepsy, cerebral gray matter atrophy), visual impairment, testicular dysgenesis in males, and sudden death at infant age by brainstem-mediated cardiorespiratory arrest. This indicates that recessive loss of function variants in *TSPYL1* are responsible for this severe and lethal progressive combined nervous and reproductive systems disease, where *TSPYL1* function seems crucial for the development or function of the brainstem as this regulates basic body functions including heart rate and breathing.

Decreased survival with cardiac edema and dysfunction as well as defects in neurogenesis were also present in *tspyl1* depleted zebrafish. Interestingly, proteomic analysis of nuclear extracts from skin fibroblasts of the affected patients also identified ‘hypertrophic cardiomyopathy’ and ‘dilated cardiomyopathy’ among the highest scored dysregulated pathways by performing enrichment analysis. It was previously shown that downregulation of the nucleosome assembly protein 1-like 1 (*Nap1l1*) significantly enhances mesodermal induction and subsequent cardiogenesis of murine-induced pluripotent stem cells via inhibition of Notch signaling (23). More recently, it was found that *nap1l1* expression in zebrafish embryos between 1 and 3 dpf maintains throughout the tectum, olfactory vesicle, lens, optic cups, heart, branchial arches, pectoral fins, axial vasculature, pronephros, and lateral line neuromasts (24). Expression studies of *tspyl1* in zebrafish embryos at 3 dpf using WISH showed expression in the brain, eye, ear, fin

and heart (data not shown). Further studies are required to define the exact role of TSPYL1 in cardiac function, but neural control could be involved. The optic tectum in zebrafish embryos has emerged as a valuable system to examine neural circuits. The optic tectum is a multilaminated structure in which tectal cell dendrites receive synapses from sensory afferents and interneurons (25). Transgenic Tg (*Ath5:eGFP*) zebrafish embryos have been developed to study tectal circuits as they label retinal ganglion cell axons that connect the eye to the brain (22). *Tsypyl1* depleted zebrafish showed significantly reduced retinal ganglion cell axons numbers in the optic tectum.

Our study also focused on the identification of the underlying pathological pathway for this disease and could provide evidence for an important role of TSPYL1 in cell cycle regulation and proliferation. Fibroblasts from patients had a reduced cell cycle G1 phase while the S and G2 phases were prolonged. The biological role of TSPYL1 was never investigated before, but a previous study showed that TSPYL2 controls the G1 checkpoint after DNA damage via gamma irradiation of mouse embryonic fibroblasts using *Tsypyl2* knockout mice (26). The SET protein was also previously shown to regulate G2/M transition by inhibition of cyclin B-CDK1 activity (27). Most TTSN proteins interact with nucleosomes via their NAP domain but have also been shown to interact with cyclin B (28-30). Cyclin B normally increases in the late S phase, peaks in the G2 phase and mitosis, and decreases during the early G1 phase (31). Interestingly, the proteomic data in the current study showed significantly elevated cyclin B3 (CCNB3) expression in nuclear extracts from the patients' fibroblasts that could be compatible with prolonged S/G2 phases. In addition, differential regulation of the cell cycle was detected as the most significant pathway in the proteomic analysis of the nuclear extracts of the patients' fibroblasts. TSPYL1 (or referred to as Q9H0U9) was previously identified as one of the 213 different nucleolar proteins

using proteomics, but was assigned in that study to the class of proteins with an unknown function (32). Additional studies are required to determine the exact role of TSPYL1 in cell cycle regulation. Defects in cell cycle regulation have been implicated in the pathogenesis of diverse multifactorial diseases, such as cancer, myocardial infarction, stroke, atherosclerosis, infection, inflammation and neurodegenerative disorders (including Alzheimer's disease) (33), but their contribution to rare Mendelian syndromes remains very limited. A recent study introduced the term 'cell cycle-opathy' for Mendelian disorders characterized by defects in DNA replication or cell cycle in patients that typically present with primordial dwarfism and microcephaly together with particular skeletal abnormalities (34).

In conclusion, with the description of three patients from a second non-Amish pedigree, this study confirms the role of TSPYL1 deficiency as cause of a progressive combined nervous and reproductive systems disease. Our data suggests that TSPYL1 deficiency probably results in a human disease via alterations in the regulation of the cell cycle.

Material and methods

Patient study

Informed consent was obtained from the legal representative (parents) of the children. The Ethics Committee of UZ Leuven approved the study (ML3580).

Exome and Sanger sequencing

Whole exome sequencing and variant filtering was performed as described (16). Sanger sequencing of PCR amplified fragments was used to validate the homozygous variants in *TSPYL1*, *ENPP3*, *SYNC*, *MRPS15*, *CACNA1C*, *PAN3* and *HR* (primers available upon request). The NCBI reference sequence for *TSPYL1* is NM_003309.4.

Antibodies

The following antibodies were used: mouse polyclonal against human TSPYL1 (MaxPab H00007259-B01P; Abnova used at 1:1000 for immunoblot and 1:50 for immunostaining), rabbit polyclonal against human HDAC1 (Clone H-51; Santa Cruz used at 1:1000 for immunoblot), rabbit monoclonal human beta-actin (Clone 13E5, Cell Signaling Technology used at 1:1000 for immunoblot) and rabbit polyclonal golgi marker Mannosidase II (Abcam used at 1:200 for immunostaining).

Human skin fibroblasts

Skin fibroblasts were obtained via punch biopsy from the volar side of the upper arm from patients P1, P2 and P4 and normal healthy subjects C1, C2, C3, C4 and C5. Fibroblasts were cultured in DMEM/H12 (Life Technologies) supplemented with 10 % fetal bovine serum and antibiotics (Life Technologies). Only fibroblasts of low passage number (between 6 and 12) were used for experiments.

Flow Cytometry to analyze cell cycling

Fibroblasts were plated (200.000 cells/6-well) and trypsinized after 24 hours, washed with PBS and fixed with ice-cold 70% ethanol for 30min at 4°C. Cells were washed with PBS and resuspended in 400 µL staining solution (20 µg/ml RNase inhibitor, 50 µg/ml propidium iodide in PBS) for 30 min at room temperature before flow cytometric analysis. We used Cell Diva software for two-color immunofluorescence acquisition on a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA) and for data analysis to determine the percentage of cells in G1, S and G2 phases. All experiments were performed in triplicate.

Immunostaining analysis

Adherent fibroblasts were washed and fixed with 4% paraformaldehyde in cytoskeleton buffer (0.1M PIPES, 2M glycerol, 1mM EDTA, 1mM MgCl₂, pH 6.9), and permeabilized for 15 minutes with 0.2% triton X-100 (Roche) at room temperature. After blocking with 1% bovine serum albumin (BSA) (Albumax, Life Technologies) for 30 minutes at room temperature, cells were incubated with a diluted primary anti-antibody overnight at 4°C. After 5 washing steps with PBS, cells were incubated with a specific secondary antibody diluted 1:200 (Alexa Fluor 488 or 568 or 647 conjugated; Life technologies) for 45 min at 37°C. Images were made with the Zeiss Elyra 5.1 (VIB BioImaging Core facility, KULeuven) for TSPYL1/mannosidase staining and with a Zeiss Axiovert microscope and captured with Zeiss AxioVision for TSPYL1/mannosidase/DAPI staining.

Immunoblot analysis

Cytosolic and nuclear fractions from fibroblast lysates were obtained by using the subcellular protein fractionation kit (Thermo Scientific) according to the instructions of the manufacturer. Protein fractions were resolved by SDS/PAGE and transferred onto a nitrocellulose membrane. Membranes were blocked in 5% milk powder in Tris-buffered saline-Tween 20 (TBST; 10 mM

Tris-HCl pH 8.0, 150 mM sodium chloride, 0.1% Tween 20) for 1 h and then incubated overnight at 4 °C with the primary antibodies. Membranes were next incubated with HRP-conjugated secondary antibody and developed by using the ECL detection reagent. Protein bands were quantified using the Bio-Rad Molecular Imager Chemi Doc™ XRS and Image Lab software version 4.0. All experiments were performed in triplicate.

Proteomic analysis of nuclear extracts by 2D-Differential In-Gel Electrophoresis (DIGE) and MS/MS analysis

Nuclear fractions from patients and controls were solubilized in sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.5) containing a mixture of protease inhibitors (Complete protease inhibitor, Roche Diagnostics). The protein concentration was determined by the Bio-Rad Dc protein assay (BioRad, Hercules, CA). Sample proteins (50 µg) were minimally labeled with 400 pmol of Cy3 or Cy5 (GE Healthcare), whereas the pooled internal standard was labeled with Cy2. The internal standard was made up of equivalent amounts of all the 8 samples. The labelling reaction, the first and second dimension and the labelled protein spot visualization were carried out as previously described (17). Briefly, gel analysis was performed using DeCyder 2-D Differential Analysis Software v6.5 (Amersham GE Healthcare). The EDA (Extended Data Analysis) module carried out intra- and inter-gel statistical analyses, performing expression pattern clustering based on PCA and ANOVA. The protein spots having a p-value <0.05 for the T-test, by applying the false discovery rate (FDR) correction method and differentially expressed between patient and controls with a fold-change of at least 1.2 were identified by mass spectrometry. To this aim, after image acquisition, gels were fixed in 50% methanol, 7% acetic acid for 1 h and then visualized with silver staining to pick spots of interest.

Mass spectrometry analysis was performed as described (17). In brief, gel pieces were cut out of a preparative gel run with 300 µg of proteins and destained. Resulting trypsin digested peptides were concentrated and desalted by using Millipore C18 ZipTips (Millipore, Bedford, MA, USA). The samples were mixed in a 1:1 (v/v) ratio with alpha-cyano-4-hydroxycinnamic acid matrix and spotted onto the MALDI target plate. MS/MS analyses were performed on a 4800 MALDI-TOF/TOF instrument (Applied Biosystems, Foster City, CA). Data interpretation was carried out using the GPS Explorer software v3.5 and database searching was performed using the Mascot program v2.0.00. MS/MS searches were conducted with the following settings: NCBI and MSDB (taxonomy set on humans) as database, MS/MS tolerance for precursor and fragment ions between 0.2 and 1Da depending on the sample, carbamidomethylation of cysteine as fixed modification, methionine oxidation as variable modification, one missed cleavage allowed in case of incomplete trypsin hydrolysis. Using these parameters the probability-based MOWSE (Molecular Weight Search) scores greater than the given cutoff value for MS/MS fragmentation data were taken as significant ($p < 0.05$).

Fibroblast proliferation assay

Fibroblasts were plated and analyzed for proliferation efficiency by using the Quick Cell proliferation assay kit (Abcam) according to the protocol of the manufacturer. All experiments were performed in triplicate.

Zebrafish injections

The ZFIN reference sequence for zebrafish *Tspyl1* is ZDB-GENE-030131-9158. Zebrafish embryos were injected at the 1-cell stage with splice morpholino (*tspyl1*-MO) CATGAGAGATGTACCTGTGCTATGT (located in exon 4 and intron 4/5) at 400 µM. Off-target effects were assessed by including a standard control MO (against beta-globin

CCTCTTACCTCAGTTACAATTTATA) at 400 μ M. MO were designed by Gene-Tools LLC (Philomath,OR). Embryos were life-screened from 1 to 5 days post fertilization (dpf) using a Zeiss Lumar V12 and images were captured with a Zeiss AxioCam MRc camera using AxioVision software (Carl Zeiss, Jena, Germany). All animal protocols were approved by the Ethical Committee of the KU Leuven. AB wild type and Tg(*Cmcl2:eGFP*) (gift from Dr HJ. Tsai, Institute of Biomedical Science, Mackay Medical College, Taiwan, 17) and Tg(*Ath5:eGFP*) (gift from Dr S Wilson, Developmental Biology Research Centre, Randall Institute, King's College, UK, 19) transgenic zebrafish lines were used.

Whole-Mount In Situ Hybridization (WISH) of zebrafish embryos

Total RNA was extracted from zebrafish embryos at various stages of development to amplify a RT-PCR fragment of the zebrafish orthologues for *lim3* (20), *slc35d3* and *pax2a* (primers available upon request). These fragments were cloned into pGEM-T-easy (Promega) for making antisense probes by linearization of the plasmid and subjected to *in vitro* transcription using the mMessage mMachine High Yield Capped RNA kit (Ambion). Developmental staging of injected zebrafish was determined by somite number and embryos were fixed in 4% paraformaldehyde. Assays for RNA expression using WISH were performed as described (21). Embryos were visualized with a Zeiss Lumar V12 or a Zeiss Axiovert microscope and images were captured with a Zeiss AxioCam MR camera using AxioVision software.

Quantification of zebrafish optic tectum

The size of the optic tectum was measured using the Tg(*ath5:eGFP*) transgenic line as described elsewhere (22). 5dpf images of dorsal views were captured with a Zeiss Lumar 100M microscope and the diameter of the optic tectum as well as the total diameter of the head were measured using AxioVision software. The ratio optic tectum/head size was assessed and p values were

calculated based on Mann Whitney test. Additional confocal images were captured on the Olympus FV1000.

Acknowledgements

This study makes use of data generated by the NIHR BioResource-Rare Disease Consortium.

This work was supported by KU Leuven BOF grant C14/19/096 and research grants from Sobi, CSL Behring and Bayer. GB is senior clinical investigator of the Research Foundation Flanders (FWO Vlaanderen, Belgium).

Conflict of Interest Statement

The authors declare no conflict of interest.

References

1. Vogel, T., Dittrich, O., Mehraein, Y., Dechend, F., Schnieders, F. and Schmidtke, J. (1998) Murine and human TSPYL genes: novel members of the TSPY-SET-NAP1L1 family. *Cytogenet. Cell. Genet.*, **81**, 265–270.
2. Park, Y.J. and Luger, K. (2006) Structure and function of nucleosome assembly proteins. *Biochem. Cell. Biol.*, **84**, 549-558.
3. Ishimi, Y. and Kikuchi, A.J (1991) Identification and molecular cloning of yeast homolog of nucleosome assembly protein I which facilitates nucleosome assembly in vitro. *Biol Chem.*, **266**, 7025-7029.
4. Simon, H.U., Mills, G.B., Kozlowski, M., Hogg, D., Branch, D., Ishimi, Y. and Siminovitch, K.A. (1994) Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. *Biochem. J.*, **297**, 389-397.
5. Marheineke, K. and Krude T.J. (1998) Nucleosome assembly activity and intracellular localization of human CAF-1 changes during the cell division cycle. *Biol. Chem.*, **273**, 15279-15286.
6. Stevens, S.J.C., van der Schoot, V., Leduc, M.S., Rinne, T., Lalani, S.R., Weiss, M.M., van Hagen, J.M., Lachmeijer, A.M.A.; CAUSES Study, Stockler-Ipsiroglu, S.G., *et al.* (2018) De novo mutations in the SET nuclear proto-oncogene, encoding a component of the inhibitor of histone acetyltransferases (INHAT) complex in patients with nonsyndromic intellectual disability. *Hum. Mutat.*, **39**, 1014-1023.

7. Qu, D., Zhang, Y., Ma, J., Guo, K., Li, R., Yin, Y., Cao, X. and Park, D.S. (2007) The nuclear localization of SET mediated by impalpha3/impbeta attenuates its cytosolic toxicity in neurons. *J. Neurochem.*, **103**, 408-422.
8. Lam, B.D., Anthony, E.C., and Hordijk, P.L. (2013) Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration. *FEBS. Lett.*, **587**, 111-119.
9. Kon, N., Wang, D., and Gu, W. (2019) Loss of SET reveals both the p53-dependent and the p53-independent functions in vivo. *Cell Death Dis.*, **10**, 237-247
10. Puffenberger, E.G., Hu-Lince, D., Parod, J.M., Craig, D.W., Dobrin, S.E., Conway, A.R., Donarum, E.A., Strauss, K.A., Dunckley, T., Cardenas, J.F., *et al.* (2004) Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. *Proc. Natl. Acad. Sci. U.S.A.*, **101**, 11689-11694.
11. Vinci, G., Brauner, R., Tar, A., Rouba, H., Sheth, J., Sheth, F., Ravel, C., McElreavey, K. and Bashamboo, A. (2009) Mutations in the TSPYL1 gene associated with 46,XY disorder of sex development and male infertility. *Fertil. Steril.*, **92**, 1347-1350.
12. Javaher, P., Stuhmann, M., Wilke, C., Frenzel, E., Manukjan, G., Grosshenig, A., Dechend, F., Schwaab, E., Schmidtke, J. and Schubert, S. (2012) Should TSPYL1 mutation screening be included in routine diagnostics of male idiopathic infertility? *Fertil. Steril.*, **97**, 402-406.
13. Hering, R., Frade-Martinez, R., Bajanowski, T., Poets, C.F., Tschentscher, F. and Riess, O. (2006) Genetic investigation of the TSPYL1 gene in sudden infant death syndrome. *Genet. Med.*, **8**, 55-58.

14. Schubert, S., Haas, C., Bartsch, C., Mirshekarnejad, M., Kohrs, S., Roettinger, I., Grosshennig, A., Stuhmann, M., Scholz, C. and Schmidtke, J. (2015) Variants in TSPYL1 are not associated with sudden infant death syndrome in a cohort of deceased infants from Switzerland. *Mol. Cell. Probes*, **29**, 31-34.
15. Slater, B., Glington, K., Dai, H., Lay, E., Karaviti, L., Mizerik, E., Murali, C.N., Lalani, S.R., Bacino, C.A. and Rossetti, L.Z. (2020) Sudden infant death with dysgenesis of the testes syndrome in a non-Amish infant: A case report. *Am. J. Med. Genet. A.*, Online ahead of print.
16. Westbury, S.K., Turro, E., Greene, D., Lentaigne, C., Kelly, A.M., Bariana, T.K., Simeoni, I., Pillois, X., Attwood, A., Austin, S., *et al.* (2015) Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. *Genome Med.*, **7**, 36-50.
17. Di Michele, M., Peeters, K., Loyen, S., Thys, C., Waelkens, E., Overbergh, L., Hoylaerts, M., Van Geet, C. and Freson, K. (2012) Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) impairs the regulation of apoptosis in megakaryocytes by activating NF- κ B: a proteomic study. *Mol. Cell. Proteomics*, **11**, M111.007625.
18. Huang, C.J., Tu, C.T., Hsiao, C.D., Hsieh, F.J. and Tsai, H.J. (2003) Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish. *Dev. Dyn.*, **228**, 30-40.
19. Masai, I., Stemple, D.L., Okamoto, H. and Wilson, S.W. (2000) Midline signals regulate retinal neurogenesis in zebrafish. *Neuron*, **27**, 251-263.

20. Glasgow, E., Karavanov, A.A. and Dawid, I.B. (1997) Neuronal and neuroendocrine expression of *lim3*, a LIM class homeobox gene, is altered in mutant zebrafish with axial signaling defects. *Dev. Biol.*, **192**, 405-419.
21. Louwette, S., Labarque, V., Wittevrongel, C., Thys, C., Metz, J., Gijsbers, R., Debyser, Z., Arnout, J., Van Geet, C. and Freson, K. (2012) Regulator of G-protein signaling 18 controls megakaryopoiesis and the cilia-mediated vertebrate mechanosensory system. *FASEB J.*, **26**, 2125-2136
22. Kay, J.N., Link, B.A. and Baier, H. (2005) Staggered cell-intrinsic timing of *ath5* expression underlies the wave of ganglion cell neurogenesis in the zebrafish retina. *Development*, **132**, 2573–2585.
23. Gong, H., Yan, Y., Fang, B., Xue, Y., Yin, P., Li, L., Zhang, G., Sun, X., Chen, Z., Ma, H., *et al.* (2014) Knockdown of nucleosome assembly protein 1-like 1 induces mesoderm formation and cardiomyogenesis via notch signaling in murine-induced pluripotent stem cells. *Stem Cells*, **32**, 1759-1773.
24. Sun, S., Li, X., Liu, Z., Zhang, G., Yang, C., Jiang, Q. and Zou, Y. (2020) Expression of nucleosome assembly protein 1 like genes in zebrafish embryos. *Gene Expr. Patterns*, **35**, 119076.
25. Meek, J. (1983) Functional anatomy of the tectum mesencephali of the goldfish. An explorative analysis of the functional implications of the laminar structural organization of the tectum. *Brain Res.*, **287**, 247-297.
26. Tao, K.P., Fong, S.W., Lu, Z., Ching, Y.P., Chan, K.W. and Chan, S.Y. (2011) TSPYL2 is important for G1 checkpoint maintenance upon DNA damage. *PLoS One*, **6**, e21602.

27. Canela, N., Rodriguez-Vilarrupla, A., Estanyol, J.M., Diaz, C, Pujol, M.J., Agell, N. and Bachs, O. (2003) The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. *J. Biol. Chem.*, **278**, 1158-1164.
28. Canela, N., Rodriguez-Vilarrupla, A., M., Estanyol, J. M., Diaz, C., Pujol, M. J., Agell, N. and Bachs, O. (2003). The SET Protein Regulates G2/M Transition by Modulating Cyclin B-Cyclin-dependent Kinase 1 Activity. *J. Biol. Chem.*, **278**, 1158-1164.
29. Kellogg, D. R. , Kikuchi, A., Fuji-Nakata, T., Turck, C. W. and Murray, A. W. (1995). Members of the NAP/SET Family of Proteins Interact Specifically with B-Type cyclins. *J. Cell Biol.*, **130**, 661-673.
30. Li, Y., and Lau, Y.F.C. (2008) TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. *Oncogene*, **27**, 6141-6150.
31. Schafer, K.A. (1998) The cell cycle: a review. *Vet. Pathol.*, **35**, 461-478.
32. Scherl, A., Couté, Y., Déon, C., Calé, A., Kindbeiter, K., Sanchez, J.C., Greco, A., Hochstrasser, D. and Diaz, J.J. (2002) Functional proteomic analysis of human nucleolus. *Mol. Biol. Cell*, **13**, 4100-4109.
33. Zhivotovsky, B. and Orrenius, S. (2010) Cell cycle and cell death in disease: past, present and future. *J. Intern. Med.*, **268**, 395-409.
34. Karaca, E., Posey, J.E., Bostwick, B., Liu, P., Gezdirici, A., Yesil, G., Coban Akdemir, Z., Bayram, Y., Harms, F.L., Meinecke, P. *et al.* (2019) Biallelic and De Novo Variants in DONSON Reveal a Clinical Spectrum of Cell Cycle-opathies with Microcephaly, Dwarfism and Skeletal Abnormalities. *Am. J. Med. Genet. A.*, **179**, 2056-2066.

Legends to figures

Figure 1. Characterization of the TSPYL1 variant at DNA and protein level. A. Pedigree with three affected (P1, P2 and P4) children who died of cardiac arrest before the first year of life and one healthy sibling (P3). The patients are homozygous for c.725_726delTG in *TSPYL1* while parents and P4 are heterozygous. B. The frameshift variant is predicted to result in a truncated protein p.Val242GluTer52 with an early STOP codon and a frameshift that disrupts the NAP

domain of TSPYL1. C. Immunoblot analysis extracts from healthy control (C) fibroblasts show TSPYL1 expression in the nuclear fraction with predicted molecular weight of 49kDa. Fibroblast extracts from the patients express a shorter protein that mainly remains in the cytoplasm fraction. The HDAC1 antibody was used to show enrichment of nuclear proteins in the nuclear fraction. M, Molecular weight (kDa). D. Immunofluorescent staining of TSPYL1 (green) and mannosidase (red) shows retention of the protein in the Golgi of patients' fibroblasts while control fibroblasts express TSPYL1 in the nucleoli. Images are representative for all analysed patient fibroblasts.

Figure 2. TSPYL1 and cell cycling. A. Experimental overview of the 2-DIGE experiment used to analyze nuclear extracts from fibroblasts of five controls and three patients and identification of differentially expressed proteins (full list in Table 1). B. The 15 proteins differentially

expressed between patients and controls and annotated as nuclear were used as input for analysis of regulatory networks using IPA (Ingenuity Pathway Analysis). The “cell cycle” pathway showed is the highest-ranked. Nodes represent proteins: colored features depict proteins identified in the present study (green: downregulated/red: upregulated, details in Table 1) whereas un-shaded features depict additional members of this network that were not detected by DIGE/MS. Node shapes indicate function: enzymes (diamond), transcription regulators (oval), nuclear receptors (rectangle), cytokines (square), transporter (trapezoid) and “other” (circles). C. Flow cytometric analysis of the cell cycle using propidium iodide staining for fibroblasts of three controls and three patients. Representative profiles with G0/1, S and G2/M phases are shown for control C1 and patient P2. D. Quantifications of triplicate flow cytometric analysis of the cell cycle for fibroblasts of three unrelated controls and three patients. Each triplicate experiment was measured in duplicate (total of six values for each individual fibroblast line). The % of cells in G0/1, S and G2/M phases are shown as mean for three controls and three patients with standard deviations. Statistical analysis was performed by one-way ANOVA with Bonferroni’s multiple comparisons test. E. Cell proliferation assay for fibroblasts cultured in 96 wells (20,000 cells/well) after 1 and 2 days of growth was assessed by a WST-1-based cell viability assay. Data are expressed as mean and standard deviation (n = 9 for each of the three controls and three patients in a triplicate experiment). Statistical analysis was performed by one-way ANOVA with Tukey’s multiple comparisons test.

Figure 3. Tspyl1 depletion in Zebrafish embryos. A. Representative images of AB embryos injected with tspyl1-MO at 3 dpf with deformed axes in contrast to c-MO injected embryos. B. Life screening of 87 AB embryos (from duplicated experiment) showed 94% of deformed embryos after tspyl1 depletion while deformed axes could not be detected in c-MO injected

embryos. Statistical analysis was performed by Fisher's exact test. C. Survival analysis of 261 *tspyl1*-MO and 273 c-MO injected AB embryos (from 4 experiments) at 5 dpf showed 52% dead fish for *tspyl1* depleted embryos and 11% for control embryos. Statistical analysis was performed by Fisher's exact test. D. Representative images of the optic tectum (arrows) in transgenic Tg(*ath5:eGFP*) embryos after injection with c-MO or *tspyl1*-MO at 5dpf. E. Quantification of the optic tectum diameter normalized by the head size for c-MO (n=64, 4 injections) or *tspyl1*-MO (n=44, 3 injections) injected embryos at 5dpf. Dots represent measurements in single embryos and the data are presented as mean and standard deviation. Statistical analysis was performed by Mann Whitney test. F. Representative images of transgenic Tg(*cmcl2:eGFP*) embryos that present with heart edema at 3dpf after *tspyl1* depletion. G. Quantification of 25 *tspyl1*-MO and 24 c-MO injected Tg(*cmcl2:eGFP*) embryos (from 1 experiment) showed edema formation near the heart in 60% of *tspyl1*-MO injected embryos at 3 dpf. Statistical analysis was performed by Mann Whitney test. H. Representative images of transgenic Tg(*cmcl2:eGFP*) embryos showed a dilated heart with inverted looping at 3dpf after *tspyl1* depletion. I. Quantification of 80 *tspyl1*-MO and 76 c-MO injected Tg(*cmcl2:eGFP*) embryos (from 3 experiments) showed defective heart looping in 682% of *tspyl1*-MO injected embryos at 3 dpf. Statistical analysis was performed by Mann Whitney test.

Table 1. Proteins from nuclear extracts differentially expressed (red up- and green down-regulation) in patients (P) compared to controls (C) ($p \leq 0.05$, P/C fold change ≥ 1.2)

Spot N°	T- test	P/C Ratio	Identification	SwissP rot code	M W (kDa)	Decoy MASC OT Score	Matchi ng peptid es
------------	------------	--------------	----------------	-----------------------	-----------------	------------------------------	------------------------------

Upregulated in fibroblasts from patients

64	0,0	2,9	Elongation factor 2		96	300	5
1	12			P13639			
64	0,0	2,2	Elongation factor 2		96	98	2
2	37			P13639			
64	0,0	2,0	Elongation factor 2		96	99	2
0	10			P13639			
11	0,0	1,9	Glucose-6-phosphate 1-dehydrogenase		60	180	7
46	05		<u>UGDH*</u>	P11413			
59	0,0	1,8	Staphylococcal nuclease domain-containing protein 1	Q7KZF4	103	220	10
1	46						
15	0,0	1,8	LIM and SH3 domain protein 1	Q14847	30	74	2
05	41						
81	0,0	1,7	78 kDa glucose-regulated protein	P11021	72	520	7
4	20						
81	0,0	1,7	Antigen KI-67 <u>MKI67*</u>	P46013	361	19	1
4	20						
11	0,0	1,7	D-3-phosphoglycerate dehydrogenase	O43175	57	302	6
43	47						
11	0,0	1,7	Tubulin beta-4B chain	P68371	50	251	6
43	47						
11	0,0	1,6	Protein disulfide-isomerase A3	P30101	57	327	6
13	01						
11	0,0	1,6	Collagen alpha-1(I) chain	P02452	140	76	2
13	01						
12	0,0	1,6	Rab GDP dissociation inhibitor beta	P50395	51	356	7
83	00						
10	0,0	1,6	UDP-glucose 6-dehydrogenase	O60701	56	59	2
95	15						
12	0,0	1,5	Prolyl 4-hydroxylase subunit alpha-1	P13674	61	47	1
35	10						
85	0,0	1,5	Prelamin-A/C <u>LMNA*</u>	P02545	74	192	4
8	09						
85	0,0	1,5	ATP-dependent RNA helicase	O00571	74	64	1
8	09						
15	0,0	1,5	Annexin A1 <u>ANXA1*</u>	P04083	39	577	9
02	27						
64	0,0	1,5	Moesin	P26038	68	125	2
5	05						
12	0,0	1,5	Spliceosome RNA helicase <u>DDX39B*</u>	Q13838	49	193	8
31	40						
11	0,0	1,5	Protein disulfide-isomerase A3	P30101	57	271	6
15	15						
11	0,0	1,5	G2/mitotic-specific cyclin-B3 <u>CCNB3*</u>	Q8WWL7	158	19	1
15	15						
78	0,0	1,5	Procollagen-lysine,2-oxoglutarate 5-	Q0280	84	257	5

3	42		dioxygenase 1	9				
12	0,0	1,4	Prolyl 4-hydroxylase subunit alpha-1	P13674	61	231	4	
26	33		<u>P4HA2*</u>					
11	0,0	1,4	Aspartate--tRNA ligase	P14868	57	125	5	
71	12							
92	0,0	1,4	Heterogeneous nuclear ribonucleoprotein	O6050	70	435	7	
7	27		<u>Q HNRPO*</u>	6				
10	0,0	1,3	Prolyl 4-hydroxylase subunit alpha-2	O1546	61	165	7	
21	43			0				
17	0,0	1,3	Heterogeneous nuclear ribonucleoprotein	P31942	37	247	4	
36	22		<u>H3 HNRH3*</u>					
17	0,0	1,3	Nucleophosmin <u>NPM*</u>	P06748	33	49	3	
36	22							
12	0,0	1,2	Septin 11					
19	54							
Downregulated in fibroblasts from patients								
12	0,0	-1,3	Actin-related protein 3			48	115	5
46	23			P61158				
94	0,0	-1,4	Lamin-B2 <u>LMNB2*</u>	Q0325	68	62	2	
9	37			2				
13	0,0	-1,4	Tubulin alpha-1C chain	Q9BQ	51	62	2	
97	49			E3				
13	0,0	-1,4	Tubulin alpha-8 chain	Q9NY	51	37	2	
97	49			65				
63	0,0	-1,5	Alpha-actinin-1	P12814	103	119	3	
5	28							
11	0,0	-1,5	Vimentin <u>VIME*</u>	P08670	54	243	7	
89	38							
13	0,0	-1,7	Actin, cytoplasmic 1 <u>ACTB*</u>	P60709	42	136	3	
94	41							
15	0,0	-1,7	Vimentin	P08670	54	103	2	
27	09							
15	0,0	-1,7	Tropomyosin alpha-1	P09493	33	100	4	
27	09							
15	0,0	-1,7	Tropomyosin beta chain	P07951	33	78	4	
27	09							
15	0,0	-1,7	Tropomyosin alpha-3 chain	P06753	33	76	4	
27	09							
15	0,0	-1,8	Tropomyosin alpha-4 chain	P67936	29	113	3	
78	26							
15	0,0	-1,8	Vimentin	P08670	54	70	2	
78	26							
17	0,0	-1,8	Tropomyosin alpha-1 chain	P09493	33	68	2	
35	16							
17	0,0	-1,8	Tropomyosin alpha-3 chain	P06753	33	44	2	
35	16							

17	0,0	-1,8	Tropomyosin beta chain	P07951	33	43	2
35	16						
17	0,0	-1,8	Vimentin	P08670	54	28	1
35	16						
11	0,0	-1,9	Vimentin	P08670	54	693	9
47	42						
11	0,0	-1,9	Nuclear mitotic apparatus protein 1	Q1498	240	30	1
47	42		<u>NUMA1*</u>	0			
11	0,0	-2,0	Vimentin	P08670	54	828	10
23	12						
11	0,0	-2,0	Vimentin	P08670	54	776	11
14	02						
13	0,0	-2,0	Actin, cytoplasmic 1	P60709	42	400	8
52	49						
13	0,0	-2,0	Actin, alpha cardiac muscle 1	P68032	42	267	4
52	49						
13	0,0	-2,0	Beta-actin-like protein 2	Q562R	42	183	2
52	49			1			
11	0,0	-2,1	Vimentin	P08670	54	837	11
19	23						
11	0,0	-2,1	Acyl-CoA dehydrogenase family member 10		120	35	2
19	23			Q6JQN			
				1			
13	0,0	-2,1	Actin, cytoplasmic 1	P60709	42	433	10
60	14						
13	0,0	-2,1	Actin, alpha cardiac muscle 1	P68032	42	246	4
60	14						
13	0,0	-2,1	Beta-actin-like protein 2	Q562R	42	172	2
60	14			1			
10	0,0	-2,1	Vimentin	P08670	54	392	10
98	04						
10	0,0	-2,1	Tetratricopeptide repeat protein 17	Q96AE	130	27	1
98	04			7			
11	0,0	-2,1	Vimentin	P08670	54	1101	15
08	15						
17	0,0	-2,3	Actin, cytoplasmic 1	P60709	42	73	3
34	07						
17	0,0	-2,3	Beta-actin-like protein 2	Q562R	42	56	2
34	07			1			
12	0,0	-2,5	Polyadenylate-binding protein 2	Q86U4	33	81	2
14	12		<u>PABP2*</u>	2			
13	0,0	-2,5	Actin, cytoplasmic 1	P60709	42	78	3
54	03						
13	0,0	-2,5	Beta-actin-like protein 2	Q562R	42	56	2
54	03			1			

*Nuclear proteins used as input list for the enrichment pathway analysis

Abbreviations

NAP	nucleosome assembly protein
TSPYL1	TSPY-like 1
TTSN	TSPY/TSPYL/SET/NAP1
SIDDT	sudden infant death with dysgenesis of the testes
MO	morpholino
Ath5	atonal-homologue 5
Tg	transgenic
dpf	days post fertilization
FDR	false discovery rate
IPA	ingenuity Pathway Analysis